Generated Narrative: CodeSystem sact-esmo-mcbs-evaluation-form

This code system https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form defines the following codes:

CodeDisplay
ST-1a Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies
ST-1b Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting
ST-2a Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
ST-2b Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
ST-2c Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
ST-3 Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR
HM-1a Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies
HM-1b Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies
HM-2a Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
HM-2b Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
HM-2c Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
HM-3 Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR
 <status value="active"/> <date value="2026-05-21T02:29:02+00:00"/> <publisher value="Te Aho o Te Kahu, Cancer Control Agency"/> <description value="The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale"/> <content value="complete"/> <count value="12"/> <concept> <code value="ST-1a"/> <display value="Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies"/> </concept> <concept> <code value="ST-1b"/> <display value="Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting"/> </concept> <concept> <code value="ST-2a"/> <display value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/> </concept> <concept> <code value="ST-2b"/> <display value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/> </concept> <concept> <code value="ST-2c"/> <display value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/> </concept> <concept> <code value="ST-3"/> <display value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/> </concept> <concept> <code value="HM-1a"/> <display value="Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies"/> </concept> <concept> <code value="HM-1b"/> <display value="Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies"/> </concept> <concept> <code value="HM-2a"/> <display value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/> </concept> <concept> <code value="HM-2b"/> <display value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/> </concept> <concept> <code value="HM-2c"/> <display value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/> </concept> <concept> <code value="HM-3"/> <display value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/> </concept> </CodeSystem>